[go: up one dir, main page]

WO1999063992A8 - Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations - Google Patents

Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations

Info

Publication number
WO1999063992A8
WO1999063992A8 PCT/US1999/012672 US9912672W WO9963992A8 WO 1999063992 A8 WO1999063992 A8 WO 1999063992A8 US 9912672 W US9912672 W US 9912672W WO 9963992 A8 WO9963992 A8 WO 9963992A8
Authority
WO
WIPO (PCT)
Prior art keywords
calcium channel
novel calcium
channel drugs
drugs
novel
Prior art date
Application number
PCT/US1999/012672
Other languages
English (en)
Other versions
WO1999063992A1 (fr
WO1999063992A9 (fr
Inventor
Yu-Hua Ji
Maya Natarajan
John H Griffin
Original Assignee
Advanced Medicine Inc
Ji Yu Hua
Maya Natarajan
John H Griffin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc, Ji Yu Hua, Maya Natarajan, John H Griffin filed Critical Advanced Medicine Inc
Priority to EP99928427A priority Critical patent/EP1085863A4/fr
Priority to CA002318901A priority patent/CA2318901A1/fr
Priority to AU45493/99A priority patent/AU4549399A/en
Priority to JP2000553061A priority patent/JP2002517440A/ja
Publication of WO1999063992A1 publication Critical patent/WO1999063992A1/fr
Publication of WO1999063992A8 publication Critical patent/WO1999063992A8/fr
Publication of WO1999063992A9 publication Critical patent/WO1999063992A9/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de nouveaux composés à liaisons multiples comprenant 2 à 10 ligands fixés par covalence, chacun de ces ligands étant capable de se lier à un site de liaison de ligand dans un canal Ca++ pour moduler les activités biologiques de ce canal.
PCT/US1999/012672 1998-06-08 1999-06-07 Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations WO1999063992A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99928427A EP1085863A4 (fr) 1998-06-08 1999-06-07 Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations
CA002318901A CA2318901A1 (fr) 1998-06-08 1999-06-07 Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations
AU45493/99A AU4549399A (en) 1998-06-08 1999-06-07 Novel calcium channel drugs and uses
JP2000553061A JP2002517440A (ja) 1998-06-08 1999-06-07 新規カルシウムチャンネル薬物および用途

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8846598P 1998-06-08 1998-06-08
US9306898P 1998-07-16 1998-07-16
US10386698P 1998-10-12 1998-10-12
US60/103,866 1998-10-12
US60/088,465 1998-12-24
US60/093,068 1998-12-24

Publications (3)

Publication Number Publication Date
WO1999063992A1 WO1999063992A1 (fr) 1999-12-16
WO1999063992A8 true WO1999063992A8 (fr) 2001-02-22
WO1999063992A9 WO1999063992A9 (fr) 2002-08-22

Family

ID=27375969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012672 WO1999063992A1 (fr) 1998-06-08 1999-06-07 Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations

Country Status (7)

Country Link
EP (1) EP1085863A4 (fr)
JP (1) JP2002517440A (fr)
AR (1) AR020876A1 (fr)
AU (1) AU4549399A (fr)
CA (1) CA2318901A1 (fr)
SG (1) SG80038A1 (fr)
WO (1) WO1999063992A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101909B2 (en) 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
EP1628663B1 (fr) 2003-05-15 2009-07-29 Roskamp Research llc Methode de preparation d'un medicament de reduction d'un depot amyloide, neurotoxicite amyloide et microgliose
ES2449594T3 (es) 2007-10-05 2014-03-20 Alzheimer's Institute Of America, Inc. Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042769A1 (de) * 1980-11-13 1982-06-09 Bayer Ag, 5090 Leverkusen C-3 verknuepfte 1,4-dihydropyridine, ihre verwendung in arzneimitteln und verfahren zu ihrer herstellung
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
ATE152917T1 (de) * 1990-09-28 1997-05-15 Neorx Corp Polymere träger zur freisetzung kovalent gebundener wirkstoffe
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
WO1996033972A1 (fr) * 1995-04-28 1996-10-31 Glaxo Group Limited Procedes de synthese de divers ensembles de pyridines, pyrimidines, derives 1,4-dihydro de ces composes et derives de piperidine
NZ280378A (en) * 1995-11-01 1998-04-27 Apotex Inc 4-phenyl-1,4-dihydropyridine-3,5-dicarboxylic acid compounds, preparation, intermediate compounds
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6403305B1 (en) * 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor

Also Published As

Publication number Publication date
WO1999063992A1 (fr) 1999-12-16
AU4549399A (en) 1999-12-30
EP1085863A1 (fr) 2001-03-28
CA2318901A1 (fr) 1999-12-16
WO1999063992A9 (fr) 2002-08-22
EP1085863A4 (fr) 2001-03-28
JP2002517440A (ja) 2002-06-18
SG80038A1 (en) 2001-04-17
AR020876A1 (es) 2002-06-05

Similar Documents

Publication Publication Date Title
ZA9710098B (en) Halogenopyrimidines.
WO2004075865A3 (fr) Modulation selective d'une activite biologique induite par le recepteur tlr
AU2508499A (en) Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof
WO2005077981A3 (fr) Polypeptides fc a nouveaux sites de liaison de ligands fc
WO2000031124A3 (fr) Peptides modulant l'interaction des ephrines de classe b avec les domaines pdz
WO1999063944A3 (fr) Nouveaux agents therapeutiques modulant les recepteurs des oestrogenes
WO2001068142A9 (fr) Systemes de ligands therapeutiques et diagnostiques pouvant lier une molecule porteuse et medicaments contenant ces ligands
WO1999011791A3 (fr) Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes
DE69634909D1 (de) Mit lumineszierenden Lanthanidchelaten markierte, biospezifisch bindende Reaktanden und ihre Verwendung
HUP0003921A3 (en) Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
IS5888A (is) Efnameðferð við krabbameini með asetýldínalíni blönduðu gemsítabíni, kapesítabíni eða sisplatíni
EP1939625A3 (fr) Procédés de découverte de ligands
DE69802615D1 (de) Triaromatische Verbindungen, diese enthaltende Zusammensetzungen sowie ihre Anwendungen
ZA98533B (en) Soluble CTLA4 mutant molecules and uses thereof.
DE69807435D1 (de) Mischer zum Mischen von Lacken, Farbstoffen od. dgl.
AU2682499A (en) Anion binding polymers and the use thereof
GB9608510D0 (en) Calcium dependent binding ligands
WO1999032509A3 (fr) Analogues d'hemiasterline
AU1974100A (en) 4-trifluoromethyl-3-oxadiazolyl pyridines, methods for the production thereof, agents containing these compounds, and their use as pesticides
DK1049721T3 (da) Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse
WO1999064040A8 (fr) Nouveaux composes de macrolides de polyene et leurs utilisations
WO1999063992A8 (fr) Nouveaux medicaments pour traiter les etats dus aux canaux calcium et leurs utilisations
WO2001012664A3 (fr) Ligands recepteurs du gene notch, et utilisations associees
CA2304130A1 (fr) Nouveau derive du ligand fas
AU2001291771A1 (en) Cycloaliphatic/aromatic diphosphines and use thereof in catalysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999928427

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase in:

Ref document number: 2318901

Country of ref document: CA

Ref country code: CA

Ref document number: 2318901

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 505978

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 45493/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000/04563

Country of ref document: ZA

Ref document number: 200004563

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 09674422

Country of ref document: US

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 553061

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWP Wipo information: published in national office

Ref document number: 1999928427

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 61-66 AND 126-131, DESCRIPTION, REPLACED BY NEW PAGES 61A-66 AND 126-131; PAGES 1/20-20/20, DRAWINGS, REPLACED BY NEW PAGES 1/25-25/25; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 1999928427

Country of ref document: EP